Located at booth 3B25 (API Hall 3), the company says it will demonstrate its ongoing commitment to advancing the global pharma market.
The company aims to continue elevating therapy development – and at this year’s CPHI it will be showcasing its first-to-market CBtru drug product intermediate and taste modulation solutions for enhanced therapy convenience and compliance.
In addition, dsm-firmenich says it will highlight how its service will continue to address evolving customer pain points within the pharmaceutical industry.
Patient-first approach to innovation
dsm-firmenich says it is excited to present the newest addition to its cannabinoid portfolio – CBtru, a cannabidiol (CBD) drug product intermediate designed for oral solid dosage forms. By enabling higher drug loading, so more of the active ingredient in the formulation, improved stability and optimized pharmacokinetic performance, the company believes CBtru is set to pave the way for more convenient and patient-friendly CBD-based medicines.
In addition, dsm-firmenich will present how its taste modulation solutions are also helping to elevate medicine acceptance.
Fernanda Onofre is global market development manager, within pharma excipients. She said: “Therapies are only effective if adhered to. However, over 60% of APIs in the market are considered bitter. That’s why, among other challenges, we’re tackling API bitterness head-on.”
“We have the capabilities to map bitterness receptors and how they interact with APIs, allowing us to develop highly effective and specific bitter blockers. These insights could have a huge impact in galenic forms especially, such as orally disintegrating tables and films and oral liquids, where the formulation components come into direct contact with the tongue.”
Also at their booth, dsm-firmenich will showcase its extensive range of ingredients – featuring GMP-compliant vitamins and vitamin derivatives and advanced flavor tonalities and taste modulators.
Onofre says: “We understand the unique and complex formulation hurdles that drug manufacturers may face – and where the right excipient can make all the difference, particularly when it comes to the taste of medicines. With a strong legacy in taste science and innovation, we are well-positioned to apply our deep knowledge and elevate pharmaceutical formulations and processes to another level.”
Ingredient-level data
Finally, dsm-firmenich says its enhanced service program helps drug developers navigate and meet the high standards and regulatory requirements of differentiated applications and markets.
“The program offers several service levels to meet specific customer needs and provides access to our broad portfolio of high-quality pharmaceutical ingredients supported by comprehensive dossiers and global market access,” says Kelsey Achenbach, vice president pharma at dsm-firmenich.
“As one of the only suppliers with EcoVadis Platinum certification, we also help our partners drive innovation with environmental responsibility at its core. This includes providing ingredient-level data and in-house Life Cycle Assessments (LCAs) expertise to help customers achieve their own sustainability targets, including Scope 3 goals. The focus on sustainability services underlines our existing platform, where we ensure our customers have the highest-level support to serve patients across the globe. Only few suppliers continue to support the continuous changing regulatory landscape and the increasingly strict quality requirements of the pharmaceutical industry. We take pride in being a reliable partner of the supply chain, to help elevate patient health with safe and effective therapies worldwide.”